Global Hospital-Acquired Pneumonia Drugs Market to Stand at US$3.8 Bn by 2020 Fueled by Imminent Launches
The incidence of healthcare associated pneumonia or global hospital-acquired pneumonia drugs market is showing a progressive increase; however, the multidrug resistance shown by microorganisms that cause nosocomial infections has created a large market for drugs that treat hospital-acquired pneumonia. According to the report, six major phase III drugs will collectively generate revenue to the tune of US$3.8 bn by 2020.These findings are detailed in the report, titled 'Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size,...
View full press release